Research programme: cell cycle protein inhibitors - Janssen/Rigel
Latest Information Update: 25 Aug 2010
At a glance
- Originator Janssen Pharmaceutica
- Class
- Mechanism of Action Cell cycle protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 03 Aug 2007 Preclinical development is ongoing
- 23 Feb 2004 This programme is still in active development
- 30 Aug 2002 This programme is still in active development